INTRODUCTION
Pseudomonas aeruginosa is a major opportunistic pathogen that can cause a wide range of nosocomial infections with fatal outcome in immunocompromised or hospitalized patients. It is also the etiologic agent of chronic airway infections in patients with cystic fibrosis, bronchiectasis, and chronic bronchitis. Antibiotics are rarely successful, due to the intrinsic and acquirable resistance mechanisms exploited by P. aeruginosa. 1 In the United States, 46,000 healthcare-associated infections due to multi-drug resistant P. aeruginosa strains are reported every year. 2 In Europe, up to 50% of clinical isolates in 2014 were resistant to at least one antibiotic class (including b lactams, aminoglycosides, and fluoroquinolones) and B14% of strains were found resistant to 43 antimicrobials. 3 In addition, P. aeruginosa exploits adaptation mechanisms to escape killing by the immune system and establish chronic infections that do not resolve. [4] [5] [6] Hence, both US and European health surveillance agencies classify P. aeruginosa as a ''serious threat'', emphasizing the urgent need for new strategies to combat its infections, limit the consequent exacerbated inflammation without immune suppression, and promote resolution. 2, 3 Pioneer work from Serhan and colleagues has demonstrated that resolution, the ideal outcome of acute inflammation, 7 is an active process controlled by endogenous specialized proresolving lipid mediators (SPM), i.e., Lipoxins (LX), 8 resolvins (Rv), 9, 10 protectins (PD) 11 and maresins (Mar) 12 that are locally produced from polyunsaturated fatty acids in select phases of inflammation and resolution. 13 Established SPM bioactions encompass the ability to limit excessive leukocyte infiltration and responses to pathogens without immune-suppression, stimulate the removal of microbes and apoptotic cells via monocyte/macrophages (MFs) phagocytosis, and protect the host from collateral tissue damage. 14 Accruing evidence signifies that SPM have potent host-protective and proresolutive bioactions in experimental inflammatory diseases, including asthma, 15 arthritis 16 and infections [17] [18] [19] [20] [21] [22] [23] (see ref. 24 for a recent review), unveiling new strategies for the pharmacotherapy of human pathologies in light of the safety and effectiveness demonstrated by SPM in preclinical and initial clinical studies. 14, 25, 26 Resolvin D1 (7S, 8R, 17S-trihydroxy-4Z, 9E, 11E, 13Z, 15E, 19Z -docosahexaenoic acid (DHA)) is an endogenous SPM enzymatically biosynthesized from DHA via lipoxygenases (LO). 27, 28 It binds 2 specific GPCRs, ALX/FPR2 and GPR32/ DRV1 to trigger cell-specific responses aimed at limiting excessive inflammation and stimulating return to homeostasis. 23 RvD1 stops polymorphonuclear neutrophil (PMN)-endothelial cell interactions and recruitment at sites of inflammation, 29 regulates specific MF microRNAs (miR) that control the release of inflammatory cytokines/chemokines and lipid mediators, 30, 31 and stimulates MF phagocytosis, 18, 32, 33 polarizing these cells towards a pro-resolutive phenotype. 34 In vivo, RvD1 promotes resolution of allergen 35 or LPS 36 -induced airway inflammation and enhances bacterial killing during acute peritonitis, skin infection, and sepsis. 18, 19 Thus, its role in P. aeruginosa lung infections is of wide interest.
Here, we demonstrate host-directed anti-microbial, anti-inflammatory, and pro-resolutive actions of RvD1 in acute and chronic lung infection triggered by a multi-drug resistant clinical strain of P. aeruginosa.
RESULTS

Lung inflammation associated with P. aeruginosa infection is markedly reduced by RvD1
To determine RvD1 actions on inflammation and bacterial clearance in preclinical models of P. aeruginosa lung infection reminiscent of human pathology, it was important to establish the temporal evolution of self-limited versus long-term lung infection with the clinical strain of P. aeruginosa RP73. Following intratracheal (i.t.) instillation of a planktonic suspension of RP73 cells (B1 Â 10 6 CFU), the bacterial titer raised up to B6.0 Â 10 6 CFU/lung 1 day post infection (DPI), decreased to B4.0 Â 10 5 CFU/lung by 3 DPI, and further dropped to o10 1 CFU/lung 7 DPI (Figure 1a) (Figure 1c) .
In sharp contrast, the inoculum of RP73 cells embedded in agar beads, which allows bacteria to survive in the host airways for a long time by growing in a microaerobic/anaerobic environment, as in the mucus of chronically infected patients, 4 ,37 caused a high-titer infection (up to B1-2 Â 10 7 CFU/lung at 5 DPI) and produced a stable colonization (B1 Â 10 6 CFU/lung) up to 21 days (Figure 1a ), in keeping with recent results. 38 This was accompanied by a steep decline in body weight in the first 3 DPI that was followed by a gradual recover during the late infection phase (Figure 1d) . A persistent significant accumulation of total leukocyte, PMN, and monocytes/MFs in BAL was also evident up to 21 DPI (Figures 1e and f) . Histological analysis revealed massive infiltration of PMN and lymphocytes in bronchial, peribronchial, alveolar and parenchymal areas in infected mice, whereas only sparse MFs were present in lungs of uninfected animals. Metaplasia of mucous secretory cells (MuSC) was also detected, as indicated by the presence of PAS þ cells in lung sections at 21 DPI, but not in uninfected controls (Figure 1g) .
To characterize the soluble components of inflammation during chronic P. aeruginosa infection, lipidometabolomics and proteomics analyses were carried out. As shown ( Figure 1h and Table 1) , leukotriene (LT) B 4 , and LTD 4 were markedly elevated at early phases (i.e. 5 DPI) of infection, while prostaglandin (PG) E 2 and other prostanoids involved in chronic inflammation were higher at 21 DPI. Of interest, several SPM (including RvD1), were below the lowest detection non-infected mice (Figure 1i) , providing a further biochemical evidence for a non resolving inflammatory state associated with a long term P. aeruginosa infection.
RvD1 treatment regulates leukocyte infiltration and lowers bacteria burden during P. aeruginosa lung infection
In this setting, we tested actions of RvD1 on P. aeruginosa clearance and inflammation. In mice challenged with planktonic RP73, a single oral administration of RvD1 (100 ng/ mouse) by intragastric gavage (chosen as a delivery mode given the lower invasiveness compared to intravenous or intratracheal injection) significantly reduced lung bacterial titer by B50% (6.03±1.9 Â 10 6 (RvD1) vs. 12.90±1.3 Â 10 6 CFU (Veh)) and BAL accumulation of total leukocytes (2.71 ± 0.47 Â 10 6 (RvD1) vs. 4.73 ± 0.73 Â 10 6 cells (Veh)), and PMN (1.70 ± 0.39 Â 10 6 (RvD1) vs. 3.34 ± 0.66 Â 10 6 PMN (Veh)) at 1 DPI (Figures 2a and b) . In contrast, oral gavage of RvE1 (100 ng/mouse), which also carries potent bioactions in airway tissues, 15 Figure 2c ) and cachexia ( Figure 2d ) in the first days following infection. This was associated to a significant reduction in IL-1b and total protein levels in BAL as well as in Evan's blue leakage in lungs (Figure 2e ) in RvD1-treated mice, which suggest that early protection conferred by RvD1 can be secondary to diminishing vascular and epithelial permeability following bacterial challenge. P. aeruginosa burden (Figure 2f ), total leukocytes, and PMN ( Figure 2g ) were also significantly lowered by RvD1 at 5 DPI, whereas monocyte/MF and lymphocyte numbers were unchanged, indicating enhancement of bacterial containment and counter-regulatory actions on leukocyte trafficking. Furthermore, while vehicle-treated animals were profoundly lethargic and poorly responsive to stimuli, mice receiving RvD1 showed a normal behavior with no apparent signs of pain (e.g., self-isolation, reduced motility, and tremor) (Supplementary Movie S1 online).
Thus, RvD1 limits the severity of P. aeruginosa pneumonia when administered early after infection.
RvD1 promotes the resolution of inflammation in infected airways and protects from tissues damage
We next asked whether RvD1 was also effective when given at the peak of infection. To this end, mice were infected with agarembedded RP73 and left untreated for 5 days, when they were randomized to receive RvD1 (100 ng/mouse) or vehicle every 48 h up to 21 DPI. Treatment with RvD1 led to a significant reduction in lung RP73 titer both at 14 (1.09±0.11 Â 10 6 (RvD1) vs. 1.81 ± 0.23 Â 10 6 CFU (Veh)) and 21 DPI (2.99 ± 2.76 Â 10 5 CFU (RvD1) vs. 2.03 ± 0.13 Â 10 6 CFU (Veh)) ( Figure 3a) . Remarkably, PMN and lymphocyte numbers in BAL decreased from 5 to 14 or 21 DPI in vehtreated mice, indicating the existence of endogenous resolution programs in response to Pseudomonas infection. RvD1 treatment further activated this program, reducing both PMN and lymphocyte numbers in BAL at 14 and 21 DPI (Figures 3b and c) , giving in a marked change in resolution indices. In particular, RvD1 reduced PMN T 50 from B12 to B10 DPI and lymphocyte T 50 from B13 to B11 DPI, giving a left-shift in the R i of B2 days ( Table 2) .
These and previous findings showing adjunctive effects of SPM and antibiotics 18, 21, 23 prompted us to test RvD1 in combination with ciprofloxacin and levofloxacin, leading drugs for P. aeruginosa infections. To this end, we first determined susceptibility of RP73 to both antimicrobials. As shown ( Table 3 ) ciprofloxacin was more potent than levofloxacin in inhibiting in vitro growth of RP73, although MIC values of both antimicrobials on RP73 were higher than those required for inhibiting the PA01 reference strain, confirming that clinical isolates of P. aeruginosa are prone to acquire resistance. 39 Consistent with this, ciprofloxacin at 200 and 400 mg/day gave a dose-dependent reduction in RP73 titer in vivo without leading to complete eradication ( Figure 3d ). Remarkably, administration of RvD1 (as low as 100 ng/day) was as potent as ciprofloxacin (given at 200 mg/day daily dose) in reducing P. aeruginosa burden ( Figure 3e ) and inflammatory cell numbers in BAL ( Figure 3f ). Of interest, the combination of the two compounds further diminished bacterial load in the airways, demonstrating that RvD1 provides additional benefits to the sole antibiotic therapy (Figure 3e ), while such additive effect was not evident on BAL leukocyte numbers.
To determine mechanisms underlying RvD1 actions, we measured phagocytosis of P. aeruginosa in vitro and in vivo, which is a defining bioaction of SPM pivotal for microbial killing. 7, 14 In vitro treatment of murine RAW 264. . BAL and lungs were collected at 1 DPI. *P ¼ 0.021; **P ¼ 0.041; ***P ¼ 0.027. Results are mean ± s.e.m. from 2 independent experiments with 11 (vehicle-treated group) and 12 (RvD1-treated group) mice. (c-e) Differences in survival, weight loss, and indexes of lung permeability. Mice receiving intratracheal inoculation of RP73-charged agar beads were treated with vehicle (0.05% vol/vol EtOH/mouse, per os) or RvD1 (100 ng/mouse/day per os) via gavage 24 h following inoculum. BAL levels of IL-1b, total proteins, and Evan's Blue amounts were determined at 5 DPI. *P ¼ 0.018; **P ¼ 0.002; ***Po0.001. Results are pooled from 2 independent experiments with 12 mice/group. V, vehicle-treated mice; R, RvD1-treated mice. (f, g) Total CFU and leukocytes in vehicle-or RvD1-treated mice infected with agar-embedded RP73 determined 5 days post agar bead inoculum. *P ¼ 0.023; ***Po0.001. Results are mean ± s.e.m. from 2 experiments with 12 mice/group.
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MucosalImmunology | VOLUME 11 NUMBER 1 | JANUARY 2018 (Figure 4a ). To measure in vivo phagocytosis, BAL leukocytes collected 5 days following infection with agar-embedded RP73 were permeabilized and incubated with an anti-P. aeruginosa antibody in order to detect ingested bacteria with flow cytometry. As shown, RvD1 gave a significant enhancement in phagocytosis of P. aeruginosa by BAL PMN and MFs 5 days following infection, which was further potentiated by ciprofloxacin co-administration as indicated by (Figure 4b) . Also, since Abdulnour and colleagues recently showed that 17R-RvD1 increases the antimicrobial protein lipocalin 2 during E. coli acute pneumonia, 21 we measured this endogenous peptide in RvD1 treated mice. As shown, RvD1 significantly increased BAL levels of lipocalin 2 at 5 DPI (Figure 4c) , demonstrating the ability to boost innate host defenses.
Since RvD1 treatment gave a significant reduction in PMN and lymphocyte accumulation in BAL of chronically infected mice, we examined if RvD1 stimulated their active removal in vivo. To this end, BAL MFs collected 14 and 21 DPI from vehor RvD1-treated mice were permeabilized and counterstained with anti-Ly6G and CD3e antibodies to detect ingested neutrophils and lymphocytes with flow cytometry (see Supplementary Method). As shown, RvD1 significantly increased phagocytosis of PMN and lymphocytes at 14 and 21 DPI, as indicated by the enhanced Ly6G-or CD3e-intracellular staining of MFs (Figure 4d) . Hence, these results highlight the existence of endogenous resolution mechanisms that are potentiated by RvD1.
To better define pro-resolution activity of RvD1, we assessed histological signs of lung inflammation and damage. Histopathological analyses revealed that RvD1 significantly decreased intraluminal granulocyte and peribronchial lymphocyte infiltrates, as well as parenchymal involvement and MuSC metaplasia (Figure 5a) . Moreover, it significantly diminished bronchiolar cell hyperplasia, as indicated by a reduction in epithelial thickness (Figure 5b) , an established histological marker of lung pathology and respiratory impairment.
Thus, RvD1 lowered P. aeruginosa-triggered lung inflammation, enhanced bacterial and leukocyte clearance and protected lung tissue from non resolving P.aeruginosa infection. 40 we searched the Ingenuity Pathway Analysis (IPA) database for miR with binding sequences to the 3 0 untranslated region of RvD1-downregulated genes and assessed their level in MFs sorted from murine lungs. IPA indicated that miR-10, -146b, and -155 can decrease MyD88 expression by binding its 3 0 untranslated region mRNA, whereas the TLR2 mRNA is a direct target of miR-21 and miR-21 and -155 regulate CXCL10, TNF-a, and IL-17 ( Figure 7a ). As shown in Figure 7b , RvD1 significantly increased miR-21 and miR-155 levels, but not miR-10 and -146b, suggesting that selected microRNAs are part of the molecular mechanisms of RvD1 actions on MFs during chronic P. aeruginosa infection.
To further validate these results, we measured cytokines, chemokines, and growth factors involved in lung inflammation in lung fluids from RvD1-or vehicle-treated infected mice. Consistent with mRNA and miRNA analyses, RvD1 significantly reduced protein levels of CCL5, CXCL10/IP10, CXCL1/KC, IL-1b, IL-17, and vascular endothelial growth factor (VEGF), all downstream effectors of the TLR-MyD88/ TRIF pathway (Figure 7c) .
Together, these results provide molecular mechanisms of RvD1 action that lower inflammatory signaling in lung MFs in response to P. aeruginosa.
For translational purposes, we assessed bioactions of RvD1 in human systems. As shown, RvD1 significantly enhanced phagocytosis of fluorescent RP73 by peripheral blood human Figure S1) . Collectively, these results indicate that RvD1 carries multipronged actions on human cells that boost host-defensive phagocytic activity against P. aeruginosa infection while limiting leukocyte recruitment and vascular responses.
DISCUSSION
P. aeruginosa is a global health threat since it sustains infections often difficult to eradicate, triggering non resolving inflammatory processes that lead to disability and death. 1 Therefore, there is an unmet need for new strategies to combat P. aeruginosa infections and inflammation. Here, we provide preclinical evidence that RvD1 is protective in acute and chronic lung infection caused by a clinical strain of P. aeruginosa. When given therapeutically to P. aeruginosainfected mice, RvD1 markedly reduced bacterial load, dampened leukocyte accumulation, enhanced bacterial clearance potentiating the efficacy of ciprofloxacin, and activated removal of infiltrated leukocytes by MFs. RvD1 protected lung tissue, reducing parenchymal inflammation, mucus metaplasia, and bronchiolar hyperplasia. Mechanistically, we demonstrated that RvD1 regulated select genes and miRNAs involved in pathogen recognition and inflammatory signaling in MFs in vivo, blunted PMN-EC interactions, and enhanced P. aeruginosa phagocytosis by human leukocytes.
The RP73 strain of P. aeruginosa used in this study is a clinical isolate derived from the airways of a cystic fibrosis patient at a late stage of infection. It is endowed with virulence factors, phenotypic traits, and adaptation capacity that confer advantages for establishing long-term infections and resistance to antibiotics. 5, 41 In order to create a stable colonization of mice lungs, P. aeruginosa must be immobilized in polysacchariderich matrices to mimic the growth in the mucus of infected patients 37 and reproduce histological hallmarks of chronic human infections. 38 Congruently, challenge with agarembedded RP73 triggered a long lasting bacterial infection in mice and a sustained inflammatory reaction characterized by leukocyte recruitment, airway tissue damage, and enhanced release of pro-inflammatory cytokines (Figure 1) . Moreover, we observed changes in the lipid mediator profile of lung tissues chronically infected with RP73. For instance, 5-LOderived LTB 4 , a primary leukocyte-derived chemoattractant, and LTD 4 , which mediates vascular permeability and bronchoconstriction, 42 as well as 5-HETE, increased rapidly after infection. This is consistent with the initial recruitment in the infected lung of PMN, which express high levels of metabolically active 5-LO. On the contrary, PGE 2 , PGF 2a , 6-keto-PGF 1a (a PGI 2 further breakdown product) and thromboxane (TX) B 2 (a TXA 2 biomarker), involved in oedema formation, vascular, and regulation of endothelial-leukocyte interactions 42 reached a maximum 21 DPI, likely as a reflection of changes in cellularity and activation of parenchymal cells. 14-HDoHE and 17-HDoHE, precursors of D-series resolvins a b Figure 5 Resolvin D1 is organ protective in chronic P. aeruginosa infection and enhances non phlogistic clearance of P. aeruginosa and inflammatory cells by macrophages. Histopathology and semiquantitative scores of (a) inflammation and mucous metaplasia and (b) bronchiolar epithelial hyperplasia of lung sections collected at 21 DPI from infected mice receiving vehicle or RvD1 (100 ng/mouse) every 48 h from day 5 following inoculum. Photomicrographs are representative from 5 mice/group. Semiquantitative scores are mean ± s.e.m. from two experiments with five mice/group. *Po0.05; **Po0.01; ***Po0.001.
and maresins, also increased during infection. Of note, although RvD1 has been identified in several mouse tissues 13, 18, 27 and, more recently, in human plasma from patients with pulmonary tuberculosis, 43 and arthritic synovial fluids, 16 it was below the LC-MS/MS detection limit in infected mice, likely reflecting the lack of proper transcellular exchanges required for RvD1 biosynthesis. 28 Lack of biosynthesis of SPM investigated here could also represent a distinct defect of chronic P. aeruginosa infection. Along this line, recent studies demonstrate that a secreted P. aeruginosa protein abundantly found in sputum of patients with cystic fibrosis disrupts the biosynthesis of 15-epi-LXA4. 44 Overall, our data are consistent with the switch, observed in humans 45 as well as in preclinical models, 13, 45, 46 in the biosynthesis of AA-derived PG and LT, which are predominant in the early phase of an inflammatory response, to SPM, which accumulate at a later time.
SPM limit the severity of infection caused by several bacterial species and promote timely resolution. For instance, RvD2 reduces mortality and bacterial dissemination after cecal ligation puncture-induced sepsis, 17 17R-RvD1 stimulates resolution of E. coli acute pneumonia, 21 and RvD1 and D5 both enhance clearance of E. coli peritonitis and S. aureus skin infection. 18 In these early studies, RvD1 and 17R-RvD1 proved to potentiate in vivo efficacy of antibiotics in eradicating infections and lowering leukocyte numbers in exudates. 18, 21 Here, effects of RvD1 plus ciprofloxacin were additive on RP73 titer, but not on BAL leukocyte and PMN counts. This may depend on the greater complexity of chronic lung infection used in this study compared to the self-resolving systems used in previous reports, or by the fact that the RP73 strain used here is a multi-drug resistant isolate evolutionarily adapted to cause persistent, non resolving lung inflammation that are resistant to therapies.
Like other SPM, does not inhibit bacterial growth per se.
17,18
Thus, enhancement of phagocytosis represents a main cellular mechanism by which they enhance resolution of infection. Consistent with this, RvD1 significantly lowered RP73 burden in self-limited and chronic infection and stimulated its phagocytosis by mouse and human phagocytes. In addition, RvD1 increased levels of lipocalin, an iron chelating protein involved in microbial killing that is also regulated by 17R-RvD1, indicating that SPM can boost both cell-mediated and humoral defense mechanisms. Together with the evidence that RvD1 can be detected in human tissues 16, 43 these results suggest that this SPM can be involved in the host response to bacterial colonization and that it has a therapeutic potential in human pharmacology, specially in clinical settings in which infections caused by multiple multi-drug resistant bacteria can occur, like in patients with cystic fibrosis.
MF from RvD1-treated mice showed enhanced capability to phagocytose PMN and lymphocytes (Figure 4) , which is in keeping with the proresolution action of RvD1, since clearance of infiltrated leukocytes by MFs is the Results are mean ± s.e.m. from 6 to 9 mice/group. *Po0.05; **Po0.01.
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hallmark of the resolution phase of inflammation. 7 Histological analysis of the lung parenchyma confirmed that RvD1 potently reduced RP73-triggered inflammation by reducing leukocyte and lymphocyte tissue infiltration, mucous secretion and bronchiolar epithelium thickness ( Figure 5 ). These results also emphasize the concept that SPM are crucial in preventing exacerbated leukocyte infiltration following infections, stimulating their removal, and ensuring tissue protection.
In vivo and in isolated cell systems RvD1 also stopped recruitment and infiltration of PMN, which have essential roles in innate defenses and clearance of P. aeruginosa, as demonstrated by preclinical and clinical studies. In experimental lung infections, neutrophil depletion in mice results in hypersusceptibility, with P. aeruginosa spreading, uncontrolled cytokine storm, and rapid death 47, 48 and neutropenic patients have a higher risk of mortality due to P. aeruginosa bacteremia and septic shock. 49 In addition, recent clinical trial evaluating the safety of BIIL 284, a LTB4 receptor antagonist that blocks PMN recruitment in the lung, was prematurely terminated because of the increased incidence of pulmonary exacerbations in patients treated with the investigational drug, likely as a consequence of the impairment in neutrophil-mediated bacterial killing, 50 highlighting the narrow risk:benefit ratio of anti-inflammatories in the context of bacterial infections. Hence, dual actions of RvD1 on neutrophils (i.e., stop of their further infiltration and enhancement of phagocytic activity) reported here and in previous studies are remarkable.
We also investigated molecular mechanisms underlying RvD1 actions in chronic P. aeruginosa lung infection and demonstrated that RvD1 regulates specific genes and proteins in lung MFs involved in leukocyte chemotaxis and infiltration (e.g., CCL5, CXCL10, and CXCL1), Th1 immune response and chronicity of airway inflammation (e.g., MyD88 and IL17), and cell activation (MyD88, TRIF, IL17) (Figures 6 and 7) . RvD1 also reduced VEGF and IL17, which stimulate cell proliferation, airway remodeling, and metaplasia 51, 52 ( Figures 6 and 7) . These results are in agreement with our findings that RvD1 limited excessive leukocyte infiltration, lung histopathology, and hyperplasia in vivo.
Of interest, many of the genes diminished by RvD1 in MF in vivo are controlled by miR-155 and miR-21, which were also upregulated by RvD1 during chronic P. aeruginosa infection. miR-155 and miR-21 have important roles in limiting the extent and the duration of inflammation. Indeed, by targeting TLRs and NF-kB, they prevent excessive or persistent stimulation of MFs that can lead to unrestrained cell activation, overshooting cytokine and ROS release, and tissue destruction, which contribute to the pathogenesis of many diseases, including chronic pneumonia and cystic fibrosis. 40, 53, 54 RvD1 carries remarkable regulatory actions on MFs via miRNAs and their target genes without suppressing their responsiveness to bacteria or other dangerous stimuli (e.g., microbial particles). During acute peritonitis induced by zymosan (a yeast cell wall component and a TLR2 ligand), and also in human MFs, RvD1 regulates miR-21, miR-146b, miR-208a, and miR-219 and their target genes as an underlying mechanism to limit overzealous MF activation, reduce inflammation, and promote resolution. 30, 31 For instance, the RvD1-regulated miR-146b targets IL-8, miR-208a controls IL-10, and miR-219 reduces 5-LO protein and biosynthesis LTB 4 , which stimulates PMN recruitment. 30 In E. coli-infected MF, RvD1 dampens the expression of pro-inflammatory genes regulated via TLRs and NF-kB such as COX-2 together with stimulating bacterial uptake. 18 Along these lines, RvD2 also reduces TLR4 expression and signaling in human monocytes via miR-146a 55 and 17R-RvD1 dampens endotoxin-and E. coliinduced activation of human macrophages, 56 indicating that regulation of MF responses through miRNAs and TLRs is a common mechanism of action of SPM. Therefore, current findings on regulation of TLRs are congruent with the established concept that RvD1 (like other SPM) finely tunes MF responses to avoid perpetuation of inflammation without blunting their host defensive properties, a concept further corroborated by the increase in P. aeruginosa clearance and phagocytosis observed in RvD1-treated mice and cells shown in the current study.
In conclusion, here we demonstrate that RvD1 is protective against persistent, non resolving inflammation caused by chronic lung infections with a clinical, multi resistant strain of P. aeruginosa. Our results unveil key cellular functions and molecular actions of RvD1 in host defense of airways mucosal tissues to pathogens, pointing to this SPM as to a prototype of new drugs to combat P. aeruginosa infections.
METHODS
Bacterial growth and mice infection. For acute infection with planktonic bacteria, the clinical strain of P. aeruginosa RP73 41 was grown in tryptic soy broth (TSB) to mid-log phase (OD 600 nm ¼ 0.45±0.05; B2 Â 10 8 CFU/mL). Bacteria were washed, suspended in Dulbecco's phosphate buffered saline (DPBS) at B2 Â 10 7 CFU/mL, and injected i.t. into mice. For chronic infection, 16 OD (B50 ml) of RP73 were included into 100-200 mm diameter tryptic soy agar (TSA) beads and used within 24 h (see Supplementary Materials and Methods). Male and female C57Bl6/N mice (8-12 week-old, 20-22 g) from Charles River (Calco, Italy) were husbanded in semi-barrier cages and fed Altromin (Rieper, Bolzano, Italy) chow pellet diet containing 7.5 g/kg o-6 linoleic acid and 1.2 g/kg (as a mixture of 18:3, 18:4, 20:5, and 22:6) fatty acids. Upon anesthesia with 2,2,2,-tribromoethanol (500 mg/kg, i.p.), 30-50 ml of planktonic or agar embedded RP73 (B3.5 Â 10 6 CFU/mouse) were injected i.t. into lungs with 22-g 0.9 Â 25 mm i.v. catheters. RvD1 (100 ng/mouse) or equal amount of vehicle (0.5% vol/vol EtOH) were administered via intragastric gavage of 0.2 ml of saline. Mice were monitored daily for clinical signs of disease and those that lost Z 20% body weight or showed evidence of severe clinical disease were euthanized before the termination of the experiment. In vitro minimal inhibitory concentrations (MIC) of ciprofloxacin and levofloxacin on the RP73 and the PA01 reference strain (LMG 27638) were determined with e-test strips (Liofilchem, Roseto degli Abruzzi, Italy). ), plating on TSA, and o.n. growth at 37 1C. Cytokines/ chemokines/growth factors were measured with Luminex (Millipore, Vimodrone, Italy) multiplex arrays except for CXCL10, that was determined with a sandwich ELISA (Peptotech, London, UK). For LC-MS/MS-based lipidomics, lungs non subjected to BAL (which could markedly modify the lipid mediator profiles) were rapidly dissociated in ice, mixed with 2 Â ice-cold methanol, and snap frozen ( À 80 1C) to prevent further degradation of lipid mediators (see Supplementary Methods and Methods for further details). To assess changes in vascular permeability, Evan's blue (100 ml/mouse of a 1% solution in saline) was injected i.p. 24 h prior lung collection. Lungs were fixed with 10% neutral buffered formalin, placed in dimethylformamide (1 ml/g of tissue) and the amount of extravasated dye was quantified on a spectrophotometer using the formula: Abs 620nm À ð1:426 À Abs 740nm þ 0:03Þ as in (ref. 57) . BAL total proteins were quantified with the Bradford method.
Lung examination and histology. Lungs excised en bloc were inflated with 1 ml of DPBS to permit even organ expansion (critical for quantitative morphometry), fixed, and cut transversally to the trachea into 5, 2 mm thick, parallel slabs/lung starting from the top 2 mm of the lung to ensure uniform random sampling. Slabs were embedded and cut surface-down into 2 mm sections that were stained with H&E or
